If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
Genentech/Roche/Chugai's Drug in Combination With Herceptin
and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory...
Mathematical modeling predicts response to Herceptin
PHILADELPHIA Cancer researchers are turning to mathematical models to help answer important clinical questions, and a new paper in Cancer Research , a journal of the American Association for Cancer Research, illustrates how the technique may answer questions about Herceptin
Long-term Use of Herceptin Does Not Increase Heart Failure in Patients
CHICAGO, A five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago states that the risk of congestive heart failure in women treated with trastuzumab (Herceptin) a...
New Zealand Says no to Herceptin Funding for Early Breast Cancer
Pharmac, the government drug funding agency has confirmed that herceptin, a drug used for treating breast cancer will remain unfunded, in spite of ongoing criticism// over the decision. The deputy medical director of Pharmac, Dilky Rasiah said that the drug is highly expensive and funding could not...
Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
Roche has made a formal application to the European Medicines Agency (EMEA) to enable the use of Herceptin
(trastuzumab) as a viable treatment// for advanced HER2-positive and hormone receptor-positive breast cancer.
The application follows the encouragement received from the international TAn...
Combination of Herceptin and Hormonal therapy to Fight Cancer
Breast cancer will soon be fought with a combined treatment of hormonal therapy and the drug, Herceptin
that has been shown to slow // the progress of breast cancer by over half, according to a recent report.
Following these findings a call has been made for the treatment to be made available fo...
Approval imminent for Herceptin in Alberta
The Alberta Cancer Board has indicated that the Klein Government is all set to give the approval to fund the drug, Herceptin, for early stage breast cancer.// The spokeswoman of the board, Lee Elliot said, they were awaiting the outcome of the clinical trials in the United Kingdom before advising t...
Latest NHS Decision on Herceptin A Boon to Breast Cancer Patients
According to the latest NHS news it is said that the breast cancer drug Herceptin
was approved to be given to all the breast cancer patients. But this is not happy news to the grieving family of Tamar Bailey. //She is 26 year old and suffered from breast cancer. But NHS officials denied her the dru...
NHS to fund Herceptin treatment for Stuart weaver Herceptin
is one of a new generation drug that can treat breast cancer. But NHS said that it would fund the treatment for patients suffering from later stages of breast cancer. // Due to this there are lots of legal challenges by cancer sufferers to force their local health care providers to pay fo...
European Medicines Agency (EMEA) Recommends Herceptin For Early Stage Breast Cancer
The European Medicines Agency (EMEA) has recommended the use of breast cancer drug Herceptin
in early stages of the cancer in a record 27 days review//. A license for the drug is to be issued in three months time.
The National Institute of Health and Clinical Excellence in the UK will decide no...
Herceptin in Medical Technology
Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three
clinical data abstracts about its oral chemotherapy treatment Xeloda(R)
have been accepted for presentation at the 2007 Breast Cancer Symposium in
San Francisco, Sept. 7 and 8. Two of the abstracts include data from the X...
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three
clinical data abstracts about its oral chemotherapy treatment Xeloda have
been accepted for presentation at the 2007 Breast Cancer Symposium in San
Francisco, Sept. 7 and 8. Two of the abstracts include data from the XeNA...
Updated Overall Survival Data From Pivotal Herceptin Adjuvant
Studies in HER2-Positive Breast Cancer
CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA)
today announced updated results from a joint analysis of two Phase
III clinical trials studying Herceptin(R) (trastuzumab) for the
adjuvant treatment of HER2-positive breast cancer. Data presented
at the 43rd Annual Meeting of the A...
Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin
Investigational cancer drug Pertuzumab shows promising results in
advanced breast cancer when combined with Herceptin
BASEL, Switzerland, June 4, 2007-Early clinical results from
Roche's trial of the exciting new cancer medicine pertuzumab, a HER
University of California Los Angeles Selects Velos eResearch
... based on basic science done in UCLA laboratories and later clinical research with UCLA patients. A few of the more well-known therapies include: herceptin
, a targeted breast cancer drug and the first approved treatment that attacks cancer at its genetic root; Gleevec , a once-a-day pill that targets a ...
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
...e I trial show that the combination of
RAD001 with herceptin
and weekly Taxol(R) (paclitaxel)** halted tumor gr...anticancer activity for RAD001 in combination with herceptin
(vinorelbine)*** in heavily pretr...t cancer. In the study, RAD001 in combination
and Navelbine halted tumor growth in 62% of patien...
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
...vanced stages of disease.
Key data being presented include:
before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
phase I...lly advanced HER2-positive
breast cancer who started a combination of herceptin
chemotherapy prior to surgery had a significantly greate...
Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
...er cheaper alternatives as the reason for
lack of reimbursement for targeted cancer therapies. Evidence has
demonstrated that patients who have failed herceptin
in the metastatic
setting should switch to Tykerb, and, according to National Cancer
Institute guidelines, patients who fail Sutent could benefit from...
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
...vessel growth in cancer cells.
"The mTOR pathway is a major route to resistance in targeted cancer
therapies, and the early data in combination with herceptin
chemotherapy demonstrate proof of concept that by inhibiting mTOR we may be
able to overcome resistance to these medicines," said David Epstein, C...
New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
The Roche data will show that Avastin and herceptin
are continuing to
offer further hope of improving ... on the importance of continued treatment with herceptin
in women with advanced metastatic breast cancer wh...e benefits that pertuzumab in combination with herceptin
could offer to patients with advanced breast c...
Herceptin in Medical Definition
... 4 Personalized medicine and cancer
5 Personalized medicine an... influenced by proven success as is the case with herceptin
and Gleevec . Theranostic tests are proving effe...e, prophylactic medications or surgery .
Two products, ...
Herceptin in Biological News
U-M study: Herceptin targets breast cancer stem cells
ANN ARBOR, Mich. A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor's growth and spread, according to a new study from the University of Michigan Comprehensive Cancer Center.
The gene, HER2, causes cancer stem cel...
Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
...ssibly be delivered through a viral vector, or administered following brain surgery.
While antibodies are used to treat a variety of cancers, such as herceptin
for breast cancer, no antibody treatment has yet been approved for brain diseases, although some are being tested, Wellstein says.
Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research
...Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including herceptin
(trastuzumab) , is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selec...
Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
...on not only as signaling manipulators but also as initiators of immune responses that leads to control of cancer, the authors say.
"We believe that herceptin
and Rituxan, as examples, work in part by immunizing people against cancer, but at this point, the magnitude of that response is variable and is frequ...
Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth
...ays that can overtake the benefits of targeted chemotherapeutics," he says.
"So in breast cancer that is HER2-positive, anti-HER2 therapies such as herceptin
will not function well if p120 has turned on alternate growth mechanisms," Dr. Anastasiadis says. "A similar effect would also be expected in EGFR-pos...
CSHL scientists identify new drug target against virulent type of breast cancer
...poorer prognoses and clinical outcomes than those who don't.
The drugs herceptin
and Lapatinib, prescribed in combination with other chemotherapeutic agents...es ErbB2, or proteins that collude with ErbB2, might nullify the effects of herceptin
and Lapatinib," explained CSHL Professor Senthil Muthuswamy, Ph.D., leader ...
Biomagnetics developed for use in new breast cancer tests
... of patients who are likely to benefit from being treated with the drug Herceptin. At a cost of 30,000 per patient per annum it is essential to target herceptin
at those women who will respond positively to it.
The team, led by Professor Pankhurst, is one of only seven groups to receive a Brian Mercer...
U-M researchers discover gene switched off in cancer can be turned on
... The finding could lead to a new class of targeted cancer therapies with potential to benefit many different cancer types.
Popular new drugs such as herceptin
and Gleevec more effectively treat cancer by targeting genetic mutations that express themselves in large amounts, causing cancer to develop. But canc...
Molecular signature may identify cisplatin-sensitive breast tumors
...r estrogen nor progesterone receptors and also do not overexpress HER2.
Since these so-called "triple-negative" tumors are treatable with neither herceptin
nor antiestrogen drugs, the prognosis for patients with the tumors has been poor. Triple-negative tumors are the most common subtype found in patient...
Tiny Tampa Bay fish key to evolution of immune system
...nically, these proteins are susceptible to enzymes that break them down. A number of such monoclonal antibody-based drugs are in clinical use, such as herceptin
for breast cancer or Avastin for colorectal cancer.
The lancelet's immune response proteins, however, are resilient. Understanding their essential ...
Herceptin in Biological Technology
First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
TCH (Taxotere, Carboplatin, Herceptin) showed a significant improvement in
Disease-Free Survival (DFS) and Overall Survival (OS), compared to AC-T
(doxorubicin and cyclophosphamide followed by docetaxel) and a 5-fold lower
cardiotoxicity compared to AC-TH (AC-T + Herceptin) in women receivin...
The Breast Cancer Therapeutics Market in Australia
...ll continue to be largely dependent on their price and availability on the Pharmaceutical Benefits Scheme (PBS)," says Gaffud.
Currently, only herceptin
(for early stage breast cancer patients) and Tykerb (for advanced/metastatic breast cancer patients) are subsidized through the PBS. Nonetheless, inno...
Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research
... at a time."
Nominations for the 2010 Dr. Paul Janssen Award will open in September and submission details will be announced at that time.
is a registered trademark of Genentech, Inc.
About The Dr. Paul Janssen Award
Established by Johnson & Johnson, The Dr. Paul Janssen Awa...
China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
...-2, also known as HER-2/neu, is a
gene that is notable for its prognostic role as well as the target of
Herceptin, a drug for breast cancer treatment. herceptin
is effective in
cancer patients whose HER-2 gene is over-expressed.
"We are excited to be the first company in China to receive SFDA
approval for ou...
Monogram Announces 2008 Third Quarter Financial Results
...as ongoing and planned clinical studies to assess HERmark as
a predictor of herceptin
response in both the metastatic and adjuvant
settings. Preliminary results ... Trofile, HERmark and VeraTag are trademarks of
Monogram Biosciences, Inc. herceptin
is a registered trademark of Genentech,
Inc. Selzentry is a trademark of P...
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
...this press release are forward-looking. These
forward-looking statements include references to the ability of the HERmark
assay to predict response to herceptin
or to significantly improve the
information available to physicians, results of studies intended to
demonstrate clinical utility of HERmark, and poten...
Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
...or determination of the likelihood of benefit
are not adequate," said Allan Lipton M.D., Profess...rceptin. Patients had been previously selected for herceptin
IHC or FISH testing, with most having b...time to progression and overall survival following herceptin
-- For TTP: HER2 total protein and...
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
...or determination of the likelihood of benefit
are not adequate," said Allan Lipton M.D., Profess...asurements will make the selection of
patients for herceptin
therapy more precise, as well as provide
quantitat...rceptin. Patients had been previously selected for herceptin
IHC or FISH testing. Using HERmark to m...
HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
...ic breast cancer who were identified as "HER2 positive" by
conventional assays suggest that HERmark can identify patients who are
likely to respond to herceptin
with greater precision than currently
available tests, permitting stratification of patients according to their
degree of clinical benefit from the dr...
Monogram Announces Third Quarter 2007 Financial Results
... of HERmark to predict patient
response in each of these clinical settings," continued Young. "We have recently begun our work in the adjuvant use of herceptin
the initiation of a pivotal study in up to 1,600 patient samples from a
well controlled and highly credible clinical study," said Young. "This